General Aspects of Chemotherapy Including “Biologic Agents”

[1]  R. Kurzrock,et al.  Equipoise lost: ethics, costs, and the regulation of cancer clinical research. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Kesari,et al.  Glioma stem cell signaling: therapeutic opportunities and challenges , 2010, Expert review of anticancer therapy.

[3]  J. Sampson,et al.  Immunotherapy Approaches for Malignant Glioma From 2007 to 2009 , 2010, Current neurology and neuroscience reports.

[4]  W. Mason,et al.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Steeg,et al.  Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer , 2009, Pharmaceutical Research.

[6]  J. Groot,et al.  Improving the prognosis for patients with glioblastoma: the rationale for targeting Src , 2009, Journal of Neuro-Oncology.

[7]  K. Black,et al.  PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model , 2008, Brain Research.

[8]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[10]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[11]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[12]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[13]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[14]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[15]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[16]  M. Prados,et al.  A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. , 2003, Neuro-oncology.

[17]  T. Batchelor,et al.  Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Pardridge.  Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.

[19]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[20]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[21]  L. Rorke,et al.  Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. , 1994, Journal of neurosurgery.